PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3513067

Augmentation mammaplasty.

L B Riddle
View original source ↗Export metadata ↓

Abstract

In the early 1900s, the best method for enlarging small breasts was to inject them with paraffin. Within 50 years, researchers turned to the free grafting of autogenous material to achieve breast enlargement. Then came the fast and easy silicone injections of the 1950s and 1960s. For the last 20 years, the surgical implantation of alloplastic materials has been used for augmentation mammaplasty. This article examines the development of augmentation mammaplasty, identifies the current procedures and looks at the possibility for overcoming the greatest complication, capsular contracture. The management of capsular contracture is difficult because it is the natural, enhanced scarring response of tissue that has been subjected to hosting a foreign body, the prosthesis. There is no simple solution to this problem, only the possibility that through manual manipulation of the augmented breast tissue, the intensity of the contracture can be minimized.

Explore related subjects

BreastFemaleHistory, 20th CenturyHumansPostoperative ComplicationsProstheses and ImplantsSiliconesSurgery, PlasticHistorical ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L B Riddle. 1986. Augmentation mammaplasty.. https://doi.org/10.1097/00006205-198603000-00005

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype.

Cancer metastasis represents the most important cause of cancer death and agents that may inhibit tumor cell invasion have been extensively pursued. In the present study, we have examined the anti-invasive effect of apicidin [cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl -L-2-amin o-8-oxodecanoyl)], a fungal metabolite that was identified as an antiprotozoal agent known to inhibit parasite histone deacetylase (HDAC). We show that apicidin significantly inhibits H-ras-induced invasive phenotype of MCF10A human breast epithelial cells in parallel with a specific downregulation of matrix metalloproteinase (MMP)-2, but not MMP-9. We also show that apicidin induces a morphological reversal and growth inhibition of H-ras MCF10A cells similar to that induced by other HDAC inhibitors. Taken in conjunction with the fact that uncontrolled ras activation is probably the most common genetic defect in human cancer cells, our data showing the anti-invasive and detransforming activities of apicidin in H-ras-transformed MCF10A cells may suggest a potential use of HDAC inhibitors for treatment of cancer.

Breast↗
PubMed2000

A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

The best current model of breast cancer evolution suggests that most cancers arise from certain premalignant lesions. We have identified a common (34%) somatic mutation in the estrogen receptor (ER)-alpha gene in a series of 59 typical hyperplasias, a type of early premalignant breast lesion. The mutation, which affects the border of the hinge and hormone binding domains of ER-alpha, showed increased sensitivity to estrogen as compared with wild-type ER-alpha in stably transfected breast cancer cells, including markedly increased proliferation at subphysiological levels of estrogen. The mutated ER-alpha exhibits enhanced binding to the TIF-2 coactivator at low levels of hormone, which may partially explain its increased estrogen responsiveness. These data suggest that this mutation may promote or accelerate the development of cancer from premalignant breast lesions.

Breast↗
PubMed2000

Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients.

Signaling through pathways involving mitogen-activated protein kinases (MAP kinases) has been implicated in the pathogenesis of cancer. Thus, the activity of MAP kinase is essential in the malignant potential of human breast tumors. p42/44(MAPK) was significantly higher expressed in tumor samples than in matching normal tissues adjacent to the tumor. p42/44(MAPK) protein expression correlated with enhanced MAP kinase activity only in a subset of tumors, indicating that over-expression of MAP kinases does not reflect the activation status of these enzymes. MAP kinase activity was significantly elevated in 131 tissue samples from primary breast tumors when compared to 18 normal tissues adjacent to tumors. A trend for higher MAP kinase activity in primary tumors of node-positive patients was observed when compared with tumors from node-negative patients. Similarly, higher MAP kinase activities were observed in specimens from patients who had a relapse within the follow-up time of 40 months when compared with patients with no relapse. A survival analysis demonstrated that the MAP kinase activity in primary breast tumors is potentially prognostic for relapse-free survival of patients.

Breast↗